RETROSPECTIVE STUDY OF ERLOTINIB IN PREVIOUSLY TREATED NSCLC PATIENTS WITH WILD-TYPE EGFR

被引：0
|
作者：
Nakahara, Yoshiro [1 ]
Hosomi, Yukio [1 ]
Yomota, Makiko [1 ]
Okuma, Yusuke [1 ]
Takagi, Yusuke [1 ]
Iguchi, Mari [1 ]
Okamura, Tatsuru [1 ]
机构：
[1] Komagome Hosp, Tokyo Metropolitan Canc & Infect Dis Ctr, Dept Thorac Oncol & Resp Med, Tokyo, Japan
来源：
JOURNAL OF THORACIC ONCOLOGY | 2012年 / 7卷 / 11期
关键词：
wild-type EGFR; Erlotinib;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2-034
引用
下载
收藏
页码：S490 / S490
页数：1
相关论文
共 50 条
  • [1] Erlotinib for Patients with EGFR Wild-Type Metastatic NSCLC: a Retrospective Biomarkers Analysis
    Inno, Alessandro
    Di Noia, Vincenzo
    Martini, Maurizio
    D'Argento, Ettore
    Di Salvatore, Mariantonietta
    Arena, Vincenzo
    Schinzari, Giovanni
    Orlandi, Armando
    Larocca, Luigi Maria
    Cassano, Alessandra
    Barone, Carlo
    PATHOLOGY & ONCOLOGY RESEARCH, 2019, 25 (02) : 513 - 520
  • [2] Metabolic tumor burden as marker of outcome in advanced EGFR wild-type NSCLC patients treated with erlotinib
    Winther-Larsen, Anne
    Fledelius, Joan
    Sorensen, Boe Sandahl
    Meldgaard, Peter
    LUNG CANCER, 2016, 94 : 81 - 87
  • [3] Activation of autophagy by erlotinib protects NSCLC cells with wild-type EGFR from erlotinib cytotoxicity
    Schwartz, Edward L.
    Ling, Yi-He
    Zou, Yiyu
    Piperdi, Bilal
    Perez-Soler, Roman
    CANCER RESEARCH, 2012, 72
  • [4] Tivantinib plus erlotinib versus placebo plus erlotinib in Asian patients with previously treated nonsquamous NSCLC with wild-type EGFR: First report of a phase III ATTENTION trial.
    Azuma, Koichi
    Yoshioka, Hiroshige
    Yamamoto, Nobuyuki
    Takahashi, Toshiaki
    Nishio, Makoto
    Katakami, Nobuyuki
    Ahn, Myung-Ju
    Hirashima, Tomonori
    Maemondo, Makoto
    Kim, Sang-We
    Noshiro, Masayoshi
    Akinaga, Shiro
    Park, Keunchil
    Tsai, Chun-Ming
    Tamura, Tomohide
    Mitsudomi, Tetsuya
    Nakagawa, Kazuhiko
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [5] Shikonin sensitizes wild-type EGFR NSCLC cells to erlotinib and gefitinib therapy
    Li, Yang-Ling
    Hu, Xiu
    Li, Qing-Yu
    Wang, Fei
    Zhang, Bo
    Ding, Ke
    Tan, Bi-Qin
    Lin, Neng-Ming
    Zhang, Chong
    MOLECULAR MEDICINE REPORTS, 2018, 18 (04) : 3882 - 3890
  • [6] Erlotinib Efficacy in NSCLC Patients with High Polysomy of Chromosome 7 and EGFR/KRas Wild-Type Tumors
    Toffalorio, Francesca
    de Marinis, Filippo
    Conforti, Fabio
    Spitaleri, Gianluca
    Catania, Chiara
    Noberasco, Cristina
    Lazzari, Chiara
    Vecchio, Fabio
    Stufano, Viviana
    Barberis, Massimo
    De Pas, Tommaso
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (02) : 392 - 396
  • [7] Predicting erlotinib resistance in EGFR wild type NSCLC patients.
    Jensen, Peter Buhl
    Knudsen, Steen
    Hansen, Anker
    Jensen, Thomas
    Askaa, Jon
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [8] A Phase II study to evaluate the efficacy of erlotinib in advanced NSCLC patients who have wild-type EGFR and EGFR gene amplification.
    Sone, Takashi
    Araya, Tomoyuki
    Tambo, Yuichi
    Shibata, Kazuhiko
    Nishikawa, Shingo
    Matsunuma, Ryo
    Kita, Toshiyuki
    Kurokawa, Koji
    Shirasaki, Hiroki
    Nishitsuji, Masaru
    Hara, Josuke
    Nomura, Satoshi
    Koba, Hayato
    Sakai, Tamami
    Touge, Hirokazu
    Ishiura, Yoshihisa
    Tamori, Shunichi
    Kimura, Hideharu
    Yoneda, Taro
    Kasahara, Kazuo
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [9] Activity of gefitinib and erlotinib in pretreated EGFR wild-type NSCLC patients: A pooled analysis of 11 randomised trials
    Barni, S.
    Gregorc, V.
    Cabiddu, M.
    Ghilardi, M.
    Borgonovo, K.
    Coinu, A.
    Cremonesi, M.
    Vigano, M. G.
    Petrelli, F.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S824 - S825
  • [10] ERLOTINIB ROLE IN PRETREATED EGFR WILD TYPE CAUCASIAN PATIENTS: A RETROSPECTIVE OBSERVATIONAL STUDY
    Gori, B.
    Del Signore, E.
    Fulvi, A.
    Ricciardi, S.
    Migliorino, M. R.
    Belli, R.
    Condo, S.
    De Santis, S.
    Colacchi, A. M.
    De Marinis, F.
    ANNALS OF ONCOLOGY, 2012, 23 : 439 - 440
12345